Freedom: safety will become a key issue for Merck’s new drug

Stock Market News

13 October 2026, 19:50

The safety profile will be a key factor in discussions with regulators regarding Merck & Co.’s (MRK) new drug for the treatment of diabetic macular edema, Freedom Broker analysts believe. Previously, the experts maintained a “Hold” rating and a $125 target price: with the shares priced at $129.40 at the time, this implied downside potential of about 3.4%.

What Merck does

Merck is one of the world’s largest pharmaceutical companies. It develops prescription medicines, vaccines, and animal health products. The main source of revenue remains the cancer drug Keytruda, which generates about half of sales.

The company is also developing new medicines, including for the treatment of eye diseases. Remigromig is intended for the treatment of diabetic macular edema— a diabetes complication in which fluid accumulation in the central part of the retina impairs vision.

Efficacy confirmed, but safety questions remain

In a Phase IIb/III study, remigromig was non-inferior in efficacy to ranibizumab, the drug it was compared against. However, complications occurred more frequently with the experimental medicine.

Freedom analysts highlight the safety profile as the key issue for further discussions with regulators. It includes the nature and frequency of adverse reactions during treatment. Thus, when evaluating the new drug, not only the therapy outcomes matter, but also the complications associated with it. 

Revenue is growing, reliance on Keytruda remains

In Q2 2026, Merck’s revenue rose 5% year over year to $16.6 billion. Sales of the Keytruda cancer-drug franchise increased 5% to $8.37 billion, including $463 million in revenue from the subcutaneous form of the drug.

New products grew faster: sales of the pulmonary hypertension drug WINREVAIR jumped 75% to $588 million, the cancer drug WELIREG rose 67% to $271 million. Sales of the pneumococcal vaccine CAPVAXIVE increased 42% and reached $184 million.

In an August assessment, Freedom Broker noted that new drugs confirm the development of the company’s portfolio, but are not yet able to offset the future loss of exclusivity for Keytruda. After patent protection expires, competition from other manufacturers may intensify.

What underpinned the “Hold” recommendation

Following the quarterly results, Merck raised its 2026 revenue guidance to $66.3–67.3 billion from $65.8–67 billion. Adjusted EPS guidance was set at $2.66–2.76, reflecting significant expenses related to deals with Cidara and Terns Pharmaceuticals.

Freedom analysts then maintained a “Hold” recommendation. In addition to dependence on Keytruda, they highlighted uncertainty around the recovery of international sales of the Gardasil vaccine, primarily in China. In Q2, sales of this product increased 4% to $1.17 billion.

The October assessment of remigromig results addresses its efficacy and safety. A new target price for the shares or a change in the recommendation is not provided in the review dated October 12.

This is not an individual investment recommendation.

16, Dostyk street, integral non-residential facility No.2, Yessil district Astana, Republic of Kazakhstan (Talan Towers Offices).

+7 7172 67 77 55 - Free from landline numbers in Kazakhstan; calls from international and mobile numbers are chargeable.

(+7 727 3557555 – additional)

7555 - free from mobile operators in Kazakhstan [email protected], [email protected]

Notify about fraudulent activities or security issues regarding this resource: fbroker.kz/trustcenter

Owning securities and other financial instruments is always associated with risks: the value of securities and other financial instruments can both rise and fall. Past investment results do not guarantee future income. In accordance with the law, the company does not guarantee or promise future returns on investments, nor does it provide guarantees regarding the reliability of potential investments or the stability of potential income.

Freedom Finance Global PLC provides brokerage (agency) services in the securities market on the territory of the Astana International Financial Center (hereinafter referred to as AFSA) in the Republic of Kazakhstan. Subject to compliance with requirements, conditions, restrictions and/or directions of the Acting Law of the AFSA, the Company is authorized to conduct the following Regulated Activities under License No. AFSA-A-LA-2020-0019: Dealing in Investments as Principal, Dealing in Investments as Agent, Managing Investments, Advising on Investments, Arranging Deals in Investments.

S&P Global ratings – “BB-”, outlook “Positive”.

Ownership of securities and other financial instruments always involves risks: the cost of securities and other financial instruments may rise or fall. Past investment results do not guarantee future returns. In accordance with the legislation, the company does not guarantee or promise the profitability of investments in the future, does not guarantee the reliability of possible investments and the stability of the amount of possible income.

The information on the website is updated as part of keeping the data up-to-date and meeting regulatory disclosure requirements. Please note that these updates are for informational purposes only and are not marketing materials!